Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months

Clinical Therapeutics

Volumn 22, Issue 3, 2000, Pages 315-325

  Schoen, Robert T ^a   Sikand, Vijay K ^b   Caldwell, Michael C ^c   Van Hoecke, C ^d   Gillet, Marc ^d   Buscarino, Charles ^e   Parenti, Dennis L ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Dutchess County Department of Health   (United States)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^e SmithKline Beecham Biologicals   (United States)

Author keywords

Immunization; Lyme disease; Recombinant outer surface protein A; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; LYME DISEASE VACCINE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SCHEDULING; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN MANIFESTATION; VOLUNTEER;

EID: 0034002761     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80035-1     Document Type: Article

References (10)

1. 1. Centers for Disease Control and Prevention. Lyme disease - United States, 1996. Morb Mortal Wkly Rep. 1997;46:533-534.
2. 2. Meek JI, Roberts CL, Smith EV Jr, et al. Underreporting of Lyme disease by Connecticut physicians, 1992. J Public Health Man Pract. 1996;2:61-65.
3. 3. Coyle BS, Strickland GT, Liang YY, et al. The public health impact of Lyme disease in Maryland. J Infect Dis. 1996;173:1260-1262.
4. 4. Nocton JJ, Steere AC. Lyme disease. In: Advances in Internal Medicine. Mosby-Year Book Inc; 1995:69-115.
5. 5. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer surface lipoprotein A with adjuvant. N Engl J Med. 1998;339:209-215.
6. 6. Van Hoecke C, Lebacq E, Beran J, Parenti D. Alternative vaccination schedule (0, 1, 6 versus 0, 1, 12 months) for a recombinant OspA Lyme disease vaccine. Clin Infect Dis. 1999;28:1260-1264.
7. 7. Van Hoecke C, Comberbach M, De Grave D, et al. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine. 1996;14:1620-1626.
8. 8. Karpinski KF, Hayward S, Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods. 1987; 103:189-194.
9. 9. World Health Organization. Dictionary for Adverse Reaction Terminology. Version 3. Basel, Switzerland: World Health Organization; 1998.
10. 10. Parenti D, Gillet M, Sennewald E, et al. Correlate of protection for Lyme disease (LD) using LYMErix™, recombinant, adjuvant Borrelia burgdorferi outer surface lipoprotein A (L-OspA) vaccine. Poster presented at: Infectious Diseases Society of America Annual Meeting; November 12-15, 1998; Denver, Colo. Abstract 705.